12770 High Bluff Drive
Suite 150
San Diego, CA 92130
United States
619-949-3681
https://www.gyretx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 593
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Han Ying Ph.D. | CEO & Director | 9,73k | S.O. | 1966 |
Mr. Songjiang Ma | President & Director | S.O. | S.O. | 1956 |
Ms. Ruoyu Chen | Chief Financial Officer | 112,51k | S.O. | 1971 |
Mr. Weiguo Ye | Chief Operating Officer | 254,6k | S.O. | 1978 |
Ms. Seline E. Miller CPA | Senior Vice President of Finance | S.O. | S.O. | 1970 |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
L’ISS Governance QualityScore de Gyre Therapeutics, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..